ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 765

Predictors of End-Stage Renal Disease in Lupus Nephritis

Mery Deeb1, Konstantinos Tselios2, Dafna D Gladman2, Jiandong Su2 and Murray Urowitz3, 1Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toront, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Nephritis, renal disease and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

End-stage renal disease (ESRD) is the most important complication of lupus nephritis (LN) and greatly affects mortality. Its incidence has been estimated at 11% at 5 years and 17% at 10 years after LN diagnosis. The identification of certain predictive factors is of importance for risk stratification and proper management. The aim of the present study was to define the factors associated with ESRD development in a defined cohort of LN patients.

Methods:

Patients with LN (class II-V according to the International Society of Nephrology/Renal Pathology Society classification) were recruited from our long-term longitudinal cohort. Individuals with ESRD (estimated glomerular filtration rate, eGFR≤15 ml/min/1.73m2) at the first two clinic visits after enrolment were excluded. Patients were followed until the occurrence of ESRD (defined as two consecutive visits with an eGFR≤15 ml/min/1.73m2 or initiation of dialysis) or last visit. They were divided in two groups (ESRD or not) and compared as per the demographic, histopathological, clinical and therapeutic variables. Statistical analysis was performed with SAS 9.0; p<0.05 was considered significant. Time-dependent Cox regression analysis was performed for the identification of predictors.

Results:

LN was diagnosed in 560 patients, 43 of whom developed ESRD (7.7%) after 7.5±6.4 years of follow up. There were no differences in demographic variables at baseline. Concerning the histopathologic class, diffuse proliferative LN (class IV) was more frequent in the ESRD patients (51.2% vs. 28.4%, p=0.033). Baseline serum creatinine was higher in the ESRD patients (152±94 vs. 85±41mmol/L, p<0.001); consequently eGFR was lower (61±37 vs. 93±37ml/min/1.73m2 respectively, p<0.001). Hypertension was more frequent in the ESRD patients (58.1 vs. 38.3%, p=0.015). Concerning laboratory values, initial proteinuria was more severe in the ESRD patients (3.2±2.5 vs. 1.9±2.8g/day, p=0.027) whereas hemoglobin was lower (113±18 vs. 120±20g/L, p=0.02). There were no differences in therapeutic variables (dose of glucocorticosteroids, type and dose of immunosuppressives and antimalarials). Patients with ESRD were using angiotensin converting enzyme inhibitors or angiotensin receptor blockers more frequently (34.9 vs. 21.3%, p=0.04). Multivariable Cox regression analysis revealed that hypertension (HR=10.1, 95%CI=4.34-23.8, p<0.001), baseline serum creatinine (HR=1.009, 85%CI=1.008-1.01, p<0.001) and initial prednisone dose (HR=1.016, 95%CI=1.001-1.031, p=0.03) were associated with a higher probability for ESRD development. On the contrary, normal hemoglobin at baseline was protective (HR=0.97, 95%CI=0.95-0.99, p<0.001).

Conclusion:

Initial serum creatinine and hypertension were the most important predictors for the development of ESRD in patients with LN. These findings reinforce the importance of regular monitoring of serum creatinine even in asymptomatic patients as well as the need for strict control of hypertension in LN.


Disclosure: M. Deeb, None; K. Tselios, None; D. D. Gladman, Abbvie, Amgen, BMS, Celgene, Eli Lilly and Company, Janssen, Novartis, Pfizer, UCB, 5,Abbvie, Amgen, Celgene, Janssen, Novartis, Pfizer and UCB, 2; J. Su, None; M. Urowitz, None.

To cite this abstract in AMA style:

Deeb M, Tselios K, Gladman DD, Su J, Urowitz M. Predictors of End-Stage Renal Disease in Lupus Nephritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/predictors-of-end-stage-renal-disease-in-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-end-stage-renal-disease-in-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology